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Abstract
Background: Celiac disease has a strong genetic association with HLA. However, this association
only explains approximately half of the sibling risk for celiac disease. Therefore, other genes must
be involved in susceptibility to celiac disease. We tested for linkage to genes or loci that could play
a role in pathogenesis of celiac disease.
Methods: DNA samples, from members of 62 families with a minimum of two cases of celiac
disease, were genotyped at HLA and at 13 candidate gene regions, including CD4, CTLA4, four T-
cell receptor regions, and 7 insulin-dependent diabetes regions. Two-point and multipoint
heterogeneity LOD (HLOD) scores were examined.
Results: The highest two-point and multipoint HLOD scores were obtained in the HLA region,
with a two-point HLOD of 3.1 and a multipoint HLOD of 5.0. For the candidate genes, we found
no evidence for linkage.
Conclusions: Our significant evidence of linkage to HLA replicates the known linkage and
association of HLA with CD. In our families, likely candidate genes did not explain the susceptibility
to celiac disease.
Background
Celiac disease (CD) is a common, familial, autoimmune
gastrointestinal disease. It is caused by sensitivity to the
dietary protein gluten, which is present in wheat, rye and
barley. Symptoms include growth failure, abdominal
pain, and diarrhea. Dermatitis herpetiformis is a cutane-
ous manifestation of CD. Complications of CD include
lymphoma, osteoporosis, anemia, and seizures. The
prevalence of CD in the US is 1:250 [1] and the ratio of
symptomatic to asymptomatic cases is between 1:5 and
1:7 [2]. Before the advent of serological testing for diag-
nosing CD, it was considered a rare disease in the US.
The clinical standard for diagnosis of CD is a small intes-
tinal biopsy showing villus atrophy and resolution of
symptoms on a gluten-free diet. However, small intesti-
nal biopsy is expensive, invasive, and often rejected by
the US patient population. The serological IgA endomy-
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sial antibody (EMA) test is a screening tool that has
greatly facilitated evaluation for CD in people with sug-
gestive symptoms and in high-risk populations. IgA
EMA testing has proven to be greater than 95% sensitive
for adults and children with classic symptomatic CD [3–
10] and greater than 98% specific in controls without
known clinical disease [11,12]. It is therefore an inexpen-
sive and specific method of screening family members
for genetic studies. Moreover, a recent study has identi-
fied symptomatic EMA positive individuals who have CD
in whom intestinal biopsies were normal with only minor
mucosal lesions. All the patients showed clinical and se-
rological recovery on a gluten-free diet. They propose
that sero-logic criteria may be more definitive in the di-
agnostic process than traditional biopsy criteria [13].
CD has a strong genetic association with the HLA class II
DQ2 genotype composed of the DQA1*05 and DQB1*02
alleles [14]. However, the HLA association alone is insuf-
ficient to explain the hereditary nature of the disease,
and is estimated to explain less than half the sibling risk
[15–18]. There appears to be genetic heterogeneity, im-
plying that more than one additional gene is involved in
the disease. With current analysis software, it is possible
to map complex traits like CD, where several genetic loci
are probably involved and the mode of inheritance is un-
clear.
One first step to identifying genes predisposing to CD is
to investigate candidate genes. Likely candidates include
the classes of genes involved in immune function, e.g., T-
cell receptor (TCR) genes and immune-modulating
genes. Other candidate genes are those from associated,
independent diseases in which there is a higher rate of
CD than in the general population, e.g., other autoim-
mune diseases such as insulin dependent diabetes melli-
tus (IDDM). These associations may be explained by
common gene(s) responsible for both diseases or the dis-
eases may share a similar autoimmune pathogenic
mechanism [19]. There have been several European
studies to localize genes for CD, but no significant evi-
dence for linkage has been reported other than at HLA
[20–29].
In this first study of families with CD from North Ameri-
ca, we investigated linkage to several candidate genes
that could play a role in the pathogenesis of CD using 62
families with at least two cases of CD.
Methods
Ascertainment of families with CD
Families with at least two cases of CD or dermatitis her-
petiformis were ascertained through local gastroenterol-
ogists, gluten intolerance support groups, and
advertising at local and national celiac disease support
meetings. There was no selection of cases based on sex or
race, although all individuals were Caucasian. None of
the families appear to be related. The research study was
approved by the University of Utah Health Sciences
Center Institutional Review Board. Participants ranged
in age from 2 years to 100+ years. Blood samples were
collected from affected individuals and their first-degree
relatives. For more distantly related cases, we also col-
lected blood from individuals that are connections be-
tween the cases. For example, for two affected
grandchildren (with different parents) and an affected
grandparent, we would collect samples from the grand-
children, their parents, and the grandparent. The break-
down of the affected individuals is shown in Table 1.
Diagnostic criteria
Medical records were obtained to confirm previous biop-
sy-proven CD or dermatitis herpetiformis. IgA EMA test-
ing was performed for participants who did not have a
biopsy proven diagnosis of CD or dermatitis herpeti-
formis. Since IgA EMA is highly sensitive and specific for
CD, we did not require biopsy confirmation for pheno-
type assignment.
IgA EMA was measured by indirect immunofluorescence
using primate smooth muscle (IMCO Diagnostics, Buffa-
lo, New York) as substrate [30]. IgA EMA titers greater
than or equal to 1:5 were considered positive. Limiting
dilution was performed on the positive sera.
Genotyping at short tandem repeat markers (STRs)
DNA was extracted from lymphocytes using PureGene
DNA isolation kits (Gentra Systems Inc.). HLA DQA1
and DQB1 genotypes were determined as described in
Feolo et al. [31]. Genotyping of DNA samples from 175 af-
fected individuals, their parents, and any connecting rel-
Table 1: Characteristics of CD Cases in the Study Population*
N (%)
Number of cases 175
Number of pedigrees 62
Number of males 55 (31%)
Number of females 120 (69%)
Diagnostic group:
D1: Intestinal biopsy 115 (66%)
D2: Skin biopsy 12 (7%)
D3: Positive serum test 48 (27%)
*Of the 175 affecteds, 90% carried the HLA DQ2 genotype, with the 
majority of the remainder being DQ8. For those affecteds diagnosed 
by serology with no biopsy, 94% had the DQ2 genotype (45/48) and 
the remaining 3 affecteds were DQ8.BMC Medical Genetics 2001, 2:12 http://www.biomedcentral.com/1471-2350/2/12
atives from 62 families was performed with 25 markers
at 13 candidate gene regions and 4 markers at HLA.
However, all families were not genotyped with all mark-
ers, because some families were collected after genotyp-
ing had been done for some of the STRs. The candidate
gene regions, markers, and chromosomal locations are
listed in Table 2. For all markers, amplification of 20 ng
genomic DNA in a total reaction mix of 10 µl was per-
formed according to standard PCR procedures, with mi-
nor modifications to optimize product clarity.
Genotyping was performed either using an ABI373 or ra-
dioactively using polyacrylamide gels. Genotypic data
were stored in the same database as all kindred and phe-
notype information.
Linkage analysis methods
Analyses were performed using dominant and recessive
genetic models, each with 2 liability classes of either af-
fected or unknown/unaffected based on diagnostic crite-
ria (Table 3). For each model, unaffected individuals and
individuals with serology or biopsy based diagnosis were
given a penetrance function based on disease prevalence.
For linkage analysis, we used the FASTLINK [32] imple-
mentation of the LINKAGE program [33,34] for two-
point analysis, and the GENEHUNTER program [35] for
both parametric and non-parametric (NPL) multi-point
analyses. Two-point linkage in the presence of locus het-
erogeneity was assessed by the admixture test of Ott, us-
ing HOMOG [36]. We used a heterogeneity LOD
(HLOD) of > 1.3 to indicate nominal evidence for linkage
for all linkage analyses [37].
Results
Candidate genes were selected based on function of those
genes (i.e., T-cell receptors, CTLA4, and CD4) or from
loci of associated diseases (i.e., IDDM). Although associ-
ated diseases were not considered in the selection of fam-
ilies, in several families, members had IDDM. In one
Table 2: Two-point and Multi-point HLODs at Markers for HLA and 13 Candidate Genes
Candidate 
gene
Chromosome Position (cM) Marker Number 
families *
Model Best two-point HLOD (α /θ )+ Positive multi-point 
HLOD(α )
CD4 12pter-pl2 16.4 CD4 44 Rec 0.0
CTLA-4 2q33 198.7 CTLA4A/G 36 Dom/Rec 0.0
198.7 CTLA4-STR 48 Dom/Rec 0.0
IDDM3 15q26 109.3 D15S107 47 Dom 0.14 (0.15/0.0) 0
115.9 D15S87 47 Dom 0.0
IDDM4 11q13 85.5 GATA30G01 47 Dom 0.29 (1.00/0.40)
IDDM5 6q25 146.1 GATA184A08 35 Dom/Rec 0.0 0.19(0.13) @ 154 cM
154.1 D6S441 45 Rec 0.15 (1.00/0.3)
154.6 GATA165G02 46 Dom/Rec 0.0
IDDM6 18q21 84.8 D18S64 41 Dom/Rec 0.0
IDDM7 6q27 173.3 D6S1277 39 Dom/Rec 0.0
187.2 D6S1027 40 Dom/Rec 0.0
IDDM9 3q22-q25 126.8 D3S3044 46 Rec 0.84 (0.05/0.0) 0.03(0.03) @ 127 cM
133.9 D3S1558 54 Rec 0.02 (0.05/0.1)
IDDM10 10p11-q11 70.2 D10S220 45 Dom 0.69 (1.00/0.20)
TCRα 14q11.2 6.5 D14S261 43 Dom 0.34 (1.00/0.30)
and 13.9 D14S283 44 Dom 0.18 (1.00/0.40)
TCRδ 22.7 D14S64 37 Dom 0.34 (1.00/0.30)
TCRβ 7q35 144.7 D7S495 45 Rec 0.25 (1.00/0.30) 0.42(0.19)@145 cM
155.1 D7S794 48 Rec 0.66 (1.00/0.20)
162.3 D7S636 37 Rec 0
TCRγ 7p15-p14 28.7 D7S507 51 Rec 0.01 (0.80/0.40) 0
34.7 D7S493 39 Rec 0.24 (1.00/0.30)
39.8 D7S529 56 Rec 0.0
41.7 D7S1808 49 Rec 0.0
HLA 6p21.3 44.4 D6S276 34 Dom 1.48 (0.95/0.10) 5.02 (0.66) @ 55 cM
49.5 D6S291 35 Dom 1.60 (1.00/0.10)
60.4 D6S426 28 Dom 3.10 (1.00/0.10)
66.4 D6S282 30 Dom 1.52 (0.45/0.00)
*There were a total of 62 families, however not all families were genotyped for all markers or missing genotypes precluded analysis in the family. + 
α  = proportion of families linked ; θ  = recombination fraction; Best HLOD from the analyses of dominant and recessive modelsBMC Medical Genetics 2001, 2:12 http://www.biomedcentral.com/1471-2350/2/12
family, a CD case, his sibling and 3 extended relatives
had IDDM; in a second family, the CD case had IDDM; in
a third family, the mother, 2 siblings, a daughter, and a
cousin of a CD case had IDDM; and in a fourth family,
the sister of a CD case had IDDM.
The highest 2-point HLOD scores obtained with either
model are shown in Table 3. The multipoint HLODs were
obtained using the same model as the 2-point HLOD
shown. The largest two-point and multi-point LOD
scores were obtained in the HLA region. Under the dom-
inant model, the two-point HLOD was 3.1 (α  = 1.0) at
D6S426 (position 60.4 cM), the multi-point HLOD was
5.02 (α  = 0.66) (position 54.6 cM), and the NPL was 4.38
(p < .0001)(position 50.2cM). The estimate for the pro-
portion of families linked was 0.66 for the multipoint
HLOD, suggesting that approximately half of the fami-
lies are linked to an HLA susceptibility locus for CD. Of
the 13 candidate gene regions investigated, none of the
regions had even nominal evidence for linkage (HLOD >
1.3) or an NPL score with p < 0.05.
Discussion
In this study, we examined linkage to a set of candidate
genes for CD. This subset of genes was selected based on
genes that could be related to CD through function or an
associated disease. For statistical and linkage analysis of
complex diseases, we used general recessive and domi-
nant models. Several biostatisticians have suggested that
general models provide power to distinguish linkage sig-
nals independent of the true underlying disease mode of
inheritance, provided both dominant and recessive mod-
els are used [38–40]. As expected, the highest two-point
and multipoint LOD scores were obtained in the HLA re-
gion, with a two-point HLOD of 3.1 and a multipoint
HLOD of 5.0. This result replicates the known associa-
tion and linkage of HLA to CD [22,25,29] and demon-
strates the power of the family resource to detect linkage
in the set of candidate gene markers.
We were interested in identifying non-HLA loci for celiac
disease. We were unable to detect even nominal evidence
for linkage at any of the loci investigated. For those re-
gions where we examined only 1 marker, it may be that
one marker was insufficient in order to detect linkage
even if it existed. A number of candidate genes investi-
gated in this study were examined previously in Europe-
an populations. Our results are in agreement with
previous linkage and/or association studies of CD and T-
cell receptor genes (TCRα , TCRγ , TCRβ , and TCRδ ),
where they saw no evidence for linkage or association, al-
though sample sizes were small [28,41]. CD28 and
CTLA-4, two genes encoding receptors that regulate T-
lymphocyte activation, are located at 2q33. Holopainen
et al [24] reported linkage and association to this region
in a study of 100 Finnish families with CD, which may
suggest a possible founder effect in these families. In a
case-control study, the CTLA-4 polymorphism, 49A>G,
was significantly associated with CD [p = 0.002 with an
odds ratio of 2.36 (95% confidence interval 1.37-4.06)]
[21]. We did not find evidence for linkage with the CTLA-
4 polymorphism.
Genomic searches for CD have been conducted in several
European populations. In 1996, Zhong et al. [29] studied
40 affected sib pairs from 11 families, and reported sig-
nificant linkage at 6p23 and weak evidence at 11p11,
7q31.3, 22cen, 15q26, 5q33.3, 19p13.1 and 19q13.2. Houl-
ston et al [42], studying 28 families, found significant ev-
idence for linkage to HLA, but no evidence for linkage to
the regions suggested by Zhong, except at 15q26, where
IDDM3 is localized. Greco et al. conducted a genome-
wide search with 39 sib pairs, and an additional 71 pairs
in regions of interest [22]. They found significant evi-
Table 3: Models used in the analysis with penetrance classes by diagnostic class (D = disease allele)
Model
Diagnosis
dd Dd DD
Dominant model (disease allele frequency = 0.0001)
Biopsy or EMA+ 0.001 0.5 0.5
Unknown/unaffected 0.001 0.001 0.001
Recessive model (disease allele frequency = 0.01)
Biopsy or EMA+ 0.001 0.001 0.5
Unknown/unaffected 0.001 0.001 0.001BMC Medical Genetics 2001, 2:12 http://www.biomedcentral.com/1471-2350/2/12
dence for linkage at HLA and nominal evidence for link-
age on 5qter and 11 qter. Using an independent set of 89
sibpairs, they reported additional linkage evidence at 5q
[23]. King et al. [26] performed a genome-wide search
with 16 CD families and reported nominal evidence for
linkage at 10q23.1 and 16q23.3. In a follow-up study with
50 families, King et al. [27] reported heterogeneity LOD
scores > 2.0 at 5 regions, including 11p11 previously re-
ported by Zhong et al. [29]. From these studies, the only
region with at least nominal evidence for linkage, which
overlapped with the candidate regions studied here, was
at IDDM3 at 15q26. One study reported possible evi-
dence for linkage [29], one reported weak evidence [42],
and two reported no linkage [20,22]. We were unable to
detect linkage.
Conclusions
Our significant evidence of linkage to HLA replicates the
known linkage and association of HLA with CD. In our
families, likely candidate genes/loci did not explain the
susceptibility to CD. It may be that these genes/loci are
not involved in CD, that we had insufficient genotyping
within regions, or that one, or a number of these genes,
has a small effect so that we were unable to detect linkage
with our set of families. We were unable to detect linkage
at IDDM3 and at CTLA4, for which positive linkages
were previously reported. This is similar to the experi-
ence in most other reported studies of celiac disease.
Non-replication of linkage results in complex diseases is
common, and may be due to the low power of studies to
detect genes of relatively small effect and/or to a high de-
gree of genetic heterogeneity among families. Larger
data sets with more power likely are needed in order to
find strong evidence for linkage.
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